Clariant stock
CLN.SWSIXClariant AG, Basic MaterialsISIN CH0012142631
61Score 61 out of 100, Neutral
Price and trend
86 / 100
Price history
+61% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 27% above it.
Since April 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 72).
The price is at its 52-week high. Largest decline in 20 years: 83% (February 2007 to March 2009).
Chart figures for advanced users
- SMA 50$12.67
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$10.56
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)72
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$8.03
- The lowest closing price of the last twelve months.
- Resistance$13.40
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Clariant AG belongs to the Chemicals (Specialty) industry (Switzerland) and, with a market value of $4.4B, is number 70 of 108 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.72B (down 5.7% year on year) and a loss of $90.38M.
- For fiscal 2026, analysts expect on average revenue of $4.65B (down 1.5%) and adjusted earnings per share of $0.80.
Show more
- MEQIRI Score 61 out of 100 (Neutral): rank 190 of 467 in Basic Materials, median 58.
- Our model puts fair value at $29.76, with the price 55% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 55% below the fair value of $29.76.Valuation 97
- High dividend yieldDividend yield 3.78%, Chemicals (Specialty) median 1.97%.
Weaknesses
- Interest barely coveredOperating profit covers interest only 1.2 times.Stability 52
- Loss-makingLoss of $36.99M over the last 12 months.Fundamentals 60
Its standout strengths are valuation and momentum, while capital allocation and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- cyclical sector (energy or materials), as a group, crashed more often in the backtest
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $22.90 and expensive above $42.52 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 5.7%. At 6.7% the fair value would be $24.70, at 4.7% it would be $37.31.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 6.6% on the twelve months before. Revenue has declined since 2006 (-4% per year), so it is worth watching closely.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 31%, operating 10%, net −2%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 23 Feb 2027in 103 days
- Last reported
- 31 Jul 2026EPS reported $0.36 (expected $0.34)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.80−2.7%
- Revenue
- $4.65B+0.7%
- Earnings per share
- $1.01−2.2%
- Revenue
- $4.8B+0.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +10.0%Expectations for 2026 unchanged: sales in local currency around flat and EBITDA margin before exceptional items of about 18%; CHF 90 million of run rate savings expected by year end.
“Our guidance for 2026 remains unchanged, with sales expected to be around 2025 levels in local currency, and an EBITDA margin of around 18% before exceptional items.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 31 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Clariant
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
467 rated companies in Basic Materials
- This company
- 61
- Sector median
- 58
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Chemicals (Specialty)
The next larger and next smaller companies by market value
- Perimeter SolutionsPRM $5.02B56
- ArkemaAKE.PA $5B50
- Dottikon ES HoldingDESN.SW $4.81B61
- Wacker ChemieWCH.DE $4.57B46
- AvientAVNT $4.24B61
- CabotCBT $3.71B61
- AshlandASH $3.51B53
- HEXPOLHPOL-B.ST $3.31B68
ETFs that hold Clariant
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi Global Bioenergy UCITS ETF EUR AccWDNR | 2.28% | 0.35% | €151.65M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.25% | 0.30% | €810.11M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.17% | 0.30% | €3.43B |
Show 5 more
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.11% | 0.39% | €1.47B |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.04% | 0.23% | €319.31M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.03% | 0.35% | €8.19B |
| UBS Core MSCI Europe UCITS ETF hEUR accUIMF | 0.02% | 0.09% | €2.97B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.